Boston Scientific Corporation vs Financial Select Sector SPDR Fund — how do they compare? Boston Scientific Corporation trades at $50.51 (market cap $74.19B), while Financial Select Sector SPDR Fund trades at $57.83. The key difference: Financial Select Sector SPDR Fund is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | XLF | |
|---|---|---|
Market Cap | $74.19B | — |
Sector | Health | — |
52-Week High | $108.14 | $58.01 |
52-Week Low | $42.63 | $47.80 |
Enterprise Value | $86.27B | — |
Signals from Pluang's Aura AI — not financial advice
BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.
Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.
XLF trades at $57.88, up 0.12% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The ETF recently crossed above its 200-day moving average, indicating positive momentum. Recent news highlights strong inflows into sector ETFs and potential opportunities from AI infrastructure financing.
The outlook for XLF is supported by technical strength and sector tailwinds, but overbought RSI levels suggest near-term caution. Key risks include interest rate sensitivity and market volatility. Analyst sentiment is generally positive, focusing on the financial sector's role in economic growth.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →